Novo Nordisk CEO on Catalent, Ozempic and Wegovy
Novo Nordisk A/S CEO Lars Fruergaard Jorgensen discusses the company's acquisition of Catalent for for $16.5 billion and the production of its weight-loss drug Wegovy and diabetes treatment Ozempic. For more on this story, please see: https://www.bloomberg.com/news/articl... -------- Follow Bloomberg for business news & analysis, up-to-the-minute market data, features, profiles and more: http://www.bloomberg.com Connect with us on... Twitter: / business Facebook: / bloombergbusiness Instagram: / bloombergbusiness
▶︎
The spirit of our founders: The values and mindsets that created Novo Nordisk a century ago
▶︎
Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine
▶︎
Novo Nordisk (Ozempic)
▶︎
Ozempic, Mounjaro users talk about changes to family life after weight loss
▶︎
Novo Nordisk CEO Lars Jorgensen testifies before Senate on weight loss drugs pricing — 9/24/24
▶︎
How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B Company
▶︎
'He's Weak': Tucker Carlson on How Trump Failed America | The Mishal Husain Show
▶︎
Why is the cryptocurrency market slumping? | Counting the Cost
▶︎
Stop Guessing About the Wegovy Pill: A Prescriber Explains All!
▶︎
What the Maker of Ozempic Doesn't Want You to Know: It's Bankrupting America
▶︎
New GLP-1 Pills Are Coming, & Wegovy May Become an Implant!
▶︎
Why GLP-1s may or may not be for you | Chasing Life
▶︎
Two U.S. service members killed, one missing in Jordan after Iranian strikes
▶︎
Ozempic maker testifies about weight loss drug prices during Senate hearing | full video
▶︎
Why Novo Nordisk’s Drugs Are Anti-Obesity Game-Changers: CNBC Healthy Returns Summit 2023
▶︎
Chinese AI Model Raises Pressure on US Spending
▶︎
Ozempic vs. Mounjaro | Which one actually protects you?
▶︎
Ozempic CEO grilled on Capitol Hill over high cost of popular weight loss drug
▶︎
Dr. Scot Gottlieb on Novo Nodrisk's oral diabetes drug, future of weight-loss drugs
▶︎